Sign In
Buy BXRX
$0.0218
+0 (+0%)
At Close: May 28, 2024
Are Options Traders Betting on a Big Move in Baudax (BXRX) Stock?
09:06am, Monday, 12'th Apr 2021
Investors need to pay close attention to Baudax (BXRX) stock based on the movements in the options market lately.
Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Thursday, 01'st Apr 2021
MALVERN, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Compensation Commit
2 Falling Knives to Catch
11:44am, Wednesday, 10'th Mar 2021
Wall Street recommends purchasing shares of Ra Medical Systems Inc (RMED) and Baudax Bio Inc (NASDAQ:BXRX), which sounds quite unexpected since these two equities have shown poor performance over the
Baudax Bio to Participate at the Oppenheimer 31st Annual Healthcare Conference
07:00am, Wednesday, 10'th Mar 2021
MALVERN, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, Presiden
Baudax Bio: A Potential Diamond In The Rough
02:47am, Tuesday, 09'th Mar 2021
Baudax Bio: A Potential Diamond In The Rough
Baudax Bio Strengthens Management Team with Appointment of Richard S. Casten as Chief Financial Officer
07:00am, Monday, 08'th Mar 2021
Company Also Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Company Also Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Baudax Bio to Present at the H.C. Wainwright Global Life Sciences Conference
07:00am, Tuesday, 02'nd Mar 2021
MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, Presiden
Is the Options Market Predicting a Spike in Baudax Bio (BXRX) Stock?
10:37am, Thursday, 18'th Feb 2021
Investors need to pay close attention to Baudax Bio (BXRX) stock based on the movements in the options market lately.
Baudax Bio, Inc. (BXRX) CEO Gerri Henwood on Q4 2020 Results - Earnings Call Transcript
01:55pm, Tuesday, 16'th Feb 2021
Baudax Bio, Inc. (BXRX) CEO Gerri Henwood on Q4 2020 Results - Earnings Call Transcript
Baudax Bio to Report 2020 Annual Financial Results and Host Conference Call and Webcast on February 16, 2021
08:05am, Wednesday, 10'th Feb 2021
MALVERN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today
Baudax Bio Announces $17.6 Million Offering Priced At-the-Market under Nasdaq Rules
03:24pm, Monday, 08'th Feb 2021
MALVERN, Pa., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today
Baudax (BXRX) to Report Q4 Earnings: What's in the Cards?
10:37am, Monday, 08'th Feb 2021
Baudax (BXRX) will provide updates on earnings and revenues when it releases results for fourth-quarter 2020.
Baudax Bio Announces Exercise of Warrants for Gross Proceeds of $13.4 Million
09:29am, Thursday, 21'st Jan 2021
MALVERN, Pa., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the agreement by an accredite
Baudax Bio Announces $12 Million Offering Priced at a Premium to Market
07:00am, Thursday, 17'th Dec 2020
MALVERN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today
Baudax Bio to Participate in the Piper Sandler 32nd Annual Healthcare Conference
04:05pm, Monday, 30'th Nov 2020
MALVERN, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, the Compan
